Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases, Financial Terms Undisclosed
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience Corporation (NASDAQ:TWST) has entered into a drug discovery agreement with Ono Pharmaceutical Co., Ltd. to discover and develop novel antibodies for the treatment of autoimmune diseases. Twist will use its Biopharma Solutions Library of Libraries for research and will receive research fees, success-based clinical and regulatory milestones, and royalties on product sales. Ono will be responsible for the development, manufacturing, and commercialization of any products resulting from the collaboration.
August 31, 2023 | 7:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience's partnership with Ono Pharmaceutical could lead to new revenue streams from research fees, milestones, and royalties. The deal could also enhance Twist's reputation in the biotech industry.
The partnership with Ono Pharmaceutical could lead to new revenue streams for Twist Bioscience from research fees, success-based clinical and regulatory milestones, and royalties on product sales. This could positively impact the company's financial performance. Additionally, the collaboration could enhance Twist's reputation in the biotech industry, potentially attracting more partnerships and customers.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100